Literature DB >> 23715874

Rescue in vitro fertilization using a GnRH antagonist in hyper-responders from gonadotropin intrauterine insemination (IUI) cycles.

Jacques Balayla1, Louis Granger, Pierre St-Michel, Marc Villeneuve, Jean-Yves Fontaine, Pascal Desrosiers, Elias M Dahdouh.   

Abstract

OBJECTIVE: To evaluate the outcomes in the conversion of high-response gonadotropin intrauterine insemination (IUI) cycles to "rescue" in vitro fertilization (IVF) using a Gonadotropin-Releasing Hormone (GnRH) antagonist, with regards to implantation rates, pregnancy rates, cost, and ovarian hyperstimulation syndrome (OHSS) as compared to matched, hyper-responder, IVF controls.
METHODS: This prospective cohort study was conducted between January 2007 and December 2009 at our institution. In order to decrease high-order multiple pregnancy, minimize the incidence of OHSS, and avoid cycle cancellation, high-response stimulated-IUI patients opted to convert to "rescue" IVF using the GnRH antagonist cetrorelix acetate. We then compared their clinical outcomes with matched patients from high-response IVF cycles of the standard long mid-luteal GnRH agonist protocol (14 or more collected oocytes). Only cases of conventional IVF without intra-cytoplasmic sperm injection (ICSI) were included in the control group.
RESULTS: Out of 184 patients undergoing stimulated-IUI cycles with gonadotropins, 87 patients developed a hyper-response, and 20 opted to convert to "rescue" IVF. These patients were compared with 157 matched, hyper responder IVF controls from our registry. The implantation rate was 25.6 % in the "rescue" IVF group and 20.7 % in the control IVF group (p < 0.0047). The ongoing clinical pregnancy rate per embryo transfer was 45.0 % and 33.6 % in the "rescue" IVF and the control IVF groups, respectively (p < 0.0001). The mean duration of stimulation was comparable between cohorts (10.0 vs.10.4 days, p = 0.6324). The mean dose of gonadotropin used per cycle was higher in the control group, 2664 international units (IU) of follicle stimulation hormone (FSH) compared to 1450 IU of FSH in the "rescue" IVF group (p < 0.0001). The incidence of severe OHSS is also higher in the control group, 5.1 % versus no cases in the "rescue" IVF group (p < 0.0001).
CONCLUSION: Our study demonstrates that conversion of high-response gonadotropin-IUI cycles to "rescue" IVF using a GnRH antagonist is a cost-effective strategy that produces better results than regular IVF with relatively minimal morbidity, and shorter duration to achieve pregnancy. Implantation and ongoing clinical pregnancy rates tend to be higher than those from hyper-responder regular IVF patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23715874      PMCID: PMC3696442          DOI: 10.1007/s10815-013-0016-z

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  15 in total

Review 1.  Are GnRH antagonists comparable to agonists for use in IVF?

Authors:  J A Huirne; R Homburg; C B Lambalk
Journal:  Hum Reprod       Date:  2007-09-14       Impact factor: 6.918

2.  Number of embryos for transfer after IVF and ICSI: a Cochrane review.

Authors:  Zabeena Pandian; Allan Templeton; Gamal Serour; Siladitya Bhattacharya
Journal:  Hum Reprod       Date:  2005-10       Impact factor: 6.918

3.  Pregnancy rate in IVF rescue in high responders to human menopausal gonadotropin.

Authors:  A Many; F Azem; J B Lessing; I Yovel; H Yavetz; A Amit
Journal:  J Assist Reprod Genet       Date:  1999-11       Impact factor: 3.412

4.  Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol.

Authors:  Hesham Al-Inany; Mohamed A Aboulghar; Ragaa T Mansour; Gamal I Serour
Journal:  Reprod Biomed Online       Date:  2005-05       Impact factor: 3.828

5.  The impact of rescue in vitro fertilization converted from high-response gonadotropin intrauterine insemination cycles in terms of implantation and pregnancy rates as compared with matched controls.

Authors:  Bulent Haydardedeoglu; Tayfun Bagis; Erhan Simsek; Tayfun Cok; Servet Ozden Hacivelioglu; Serkan Erkanli
Journal:  Fertil Steril       Date:  2008-08-09       Impact factor: 7.329

6.  A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial.

Authors:  Richard H Reindollar; Meredith M Regan; Peter J Neumann; Bat-Sheva Levine; Kim L Thornton; Michael M Alper; Marlene B Goldman
Journal:  Fertil Steril       Date:  2009-06-16       Impact factor: 7.329

7.  The effect of the new 2010 World Health Organization criteria for semen analyses on male infertility.

Authors:  Katie S Murray; Andrew James; James B McGeady; Michael L Reed; Wayne W Kuang; Ajay K Nangia
Journal:  Fertil Steril       Date:  2012-08-24       Impact factor: 7.329

Review 8.  Gonadotrophins for idiopathic male factor subfertility.

Authors:  A M Attia; H G Al-Inany; C Farquhar; M Proctor
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

Review 9.  Strategies to reduce multiple pregnancies due to ovulation stimulation.

Authors:  Richard Palmer Dickey
Journal:  Fertil Steril       Date:  2008-10-29       Impact factor: 7.329

Review 10.  Clinical effectiveness of elective single versus double embryo transfer: meta-analysis of individual patient data from randomised trials.

Authors:  D J McLernon; K Harrild; C Bergh; M J Davies; D de Neubourg; J C M Dumoulin; J Gerris; J A M Kremer; H Martikainen; B W Mol; R J Norman; A Thurin-Kjellberg; A Tiitinen; A P A van Montfoort; A M van Peperstraten; E Van Royen; S Bhattacharya
Journal:  BMJ       Date:  2010-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.